Can a drug make radiation work better against aggressive brain tumors?

NCT ID NCT00209989

Completed Disease control Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the drug ZARNESTRA to standard radiation therapy can slow tumor growth in people with glioblastoma, an aggressive brain cancer. Twenty-seven patients took the drug daily starting a week before radiation and continuing through treatment. The main goal was to see how long it took for the cancer to progress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZARNESTRA (a drug that may make cancer cells more sensitive to radiation)
What this could lead to: If it works, this could point toward a way to slow glioblastoma progression by combining a drug with standard radiation.
What could go wrong: This is a small, early-phase study (27 people) with no control group, so results may not be conclusive. The drug may not improve outcomes or could add side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Centre Jean Perrin

Clermont-Ferrand, France
Institut Claudius Regaud

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.